AC Immune S.A.
ACIU · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.18 | -0.06 | 0.01 | -0.13 |
| FCF Yield | -9.86% | -11.55% | 2.17% | -4.07% |
| EV / EBITDA | -6.88 | -8.23 | -15.68 | 53.16 |
| Quality | ||||
| ROIC | -21.01% | -17.16% | -14.20% | 5.05% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 1.16 | 0.74 | 0.99 | -0.38 |
| Growth | ||||
| Revenue 3-Year CAGR | 1,535.16% | 94.42% | 93.02% | 90.75% |
| Free Cash Flow Growth | 16.72% | -428.17% | 140.83% | -119.62% |
| Safety | ||||
| Net Debt / EBITDA | 1.01 | 0.81 | 2.02 | -4.84 |
| Interest Coverage | -387.76 | -358.70 | -620.60 | 220.27 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 146.85 | 264.82 | 174.38 | 83.90 |